Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 242 (LINC00242) is a long non-coding RNA (lncRNA) categorized specifically as a long intergenic non-coding RNA, meaning it is transcribed from genomic regions not overlapping protein-coding genes[1]. LINC00242 functions in part by modulating gene expression and has been shown to play an oncogenic role in gastric cancer by promoting cell proliferation and aerobic glycolysis through the LINC00242/miR-1-3p/G6PD axis; it acts as a molecular sponge for miR-1-3p, thereby permitting increased expression of G6PD and promoting metabolic reprogramming in cancer cells[2]. LINC00242 is not a protein, receptor, enzyme, or traditional drug target, but is significant for its function in cancer progression and possible value as a biomarker. Its dysregulation is associated with worse outcomes in cancer models, supporting its emerging significance in tumor biology[2].
Regulation through the LINC00242/miR-1-3p/G6PD axis; LINC00242 acts as a molecular sponge for miR-1-3p, thereby relieving miR-1-3p-mediated suppression of G6PD expression, affecting proliferation and glycolysis in gastric cancer cells[2]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 242 (LINC00242).